99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. - Wikidata - wikimedia - TriplyDB

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

http://www.wikidata.org/entity/Q39144187

about

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Prostate-specific membrane antigen as a target for cancer imaging and therapy In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging The elements of life and medicines Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design.Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse Development of targeted near-infrared imaging agents for prostate cancer [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.Molecular imaging of urogenital diseases.Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.Vectors for the delivery of radiopharmaceuticals in cancer therapeutics.⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling.Small-molecule PSMA ligands. Current state, SAR and perspectives.Small Molecules for Active Targeting in Cancer.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease (99m) Tc radiolabeling and biological evaluation of nanoparticles functionalized with a versatile coating ligand.Chemically synthesized molecules with the targeting and effector functions of antibodies.Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.Metal-Based PSMA Radioligands.Technetium-99m radiochemistry for pharmaceutical applications.Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model.Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen.Current status of theranostics in prostate cancer.99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.Convenient Preparation of [(68)Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy.Synthesis and comparative in vivo evaluation of 99m Tc(CO)3 -labeled PEGylated and non-PEGylated cRGDfK peptide monomers.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007.[(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.PSMA Theranostics: Current Status and Future Directions.

P2860

Q26774920-B92D2748-2583-4578-A8EE-433CA0F73FFC Q26799439-E4A53E93-0E82-4B7D-B207-7D3DF6320EBC Q28535729-FA145F5F-798D-4BC3-8C62-CE9C6CF326E2 Q28649323-808D44AD-0196-49EA-A605-7ADE4A583F43 Q30383551-501BC7D8-2400-4F4C-B034-6C91029E85C8 Q33586706-E0609F84-7B6B-42F6-8642-4284281357D9 Q33668676-9649E6B4-9508-4F79-BEAD-0A7BDA49DE41 Q35754837-1B979188-1556-41D4-B636-7C463A7808A3 Q36867784-39E01414-F48F-4933-9486-D6ECA68AB0DB Q37390674-44A7C398-CC12-4378-9302-78C5008A7D08 Q37550399-97DAF361-1BA7-4895-BE19-87C24519F7F0 Q37559487-C49E3E68-1B89-4501-8E6E-606165985B47 Q37662752-C0CCF5CA-51F7-4199-9BD2-855331481345 Q38261959-9AFC62ED-8AC8-4827-9CF8-4D25CE839D28 Q38705627-C6B21185-AC44-4513-96DB-88A81A1533DA Q38707752-DE70E7B5-D2FF-45E3-9A3B-C5A66C6E8295 Q38737674-D8A734DB-38B4-418C-978E-495AF9A78E5B Q38780383-98BF9AAD-28C2-4E30-B0E7-53BA4DEBE918 Q38831232-640214BF-C030-4956-ABD9-455A730AB46B Q38900624-FB4E3C04-1EAF-400B-B7FA-4DA411B094C4 Q38928032-2244DB29-65D0-4106-9246-3A8511986770 Q38971971-7B34D217-3F54-412E-B85C-0A309CF3E2CB Q39017235-6E04F17A-2963-443C-8A5A-5DB2DB8930FB Q39198527-A5DF52DB-2462-430C-ACF2-073CCEE5D49E Q39375826-FB8BA7BB-5280-4C87-91E4-8B443725BA74 Q39697612-76D46A20-9DB6-4998-B755-BC51DBD49CF9 Q42756624-F60D5656-5647-44D4-9108-1755A76C7410 Q47105948-D2203C54-847F-4008-BD28-4CD8AA64F0A4 Q47241139-80F56F38-C1A2-4D45-9001-44C2C57880A8 Q47438555-511D8C37-8216-4590-B5F8-4664C371D0B8 Q48226060-07C3BB07-CF04-4938-A7A2-564942D69344 Q51440427-4A003CB0-FD7D-4D76-A2AC-43D4DB68BEC3 Q51550439-3C3F8882-E7DA-4586-82F8-D61C87A7A6B4 Q52565554-AF73F362-6386-4E5E-81A2-EB89A4CA0D3C Q52590598-535F10EF-866D-46E6-8CF0-ED0484CAC3FF Q53031006-10355B7C-4CCF-4A3E-977A-380F9802DCC0 Q53070213-4525AFC9-6FA8-4E24-8FB8-FEF1707351DE Q55023828-99E36D29-75AA-4D4A-90BC-908949F208B3

P2860

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

http://www.wikidata.org/entity/Q39144187

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@en

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@nl

type

label

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@en

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@nl

prefLabel

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@en

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@nl

P1433

Q39144187-0A7379D8-B0DA-4B8F-B2DA-5A0C07D2F5CD

P1476

Q39144187-2BE79FAF-B237-4A49-BDB2-994A02A2B819

P2093

Q39144187-5D0CF66B-B8F2-4990-AD1F-30E9ADD1AD65

Q39144187-5EA78BD0-FDAB-4705-84AE-34C631AEF792

Q39144187-61549C35-6C37-4F1F-A230-E34166A4ECF4

Q39144187-6C2FD763-CA47-482F-8653-00EB15428580

Q39144187-B2871208-6233-444C-AFF1-88FB6C6E465F

Q39144187-D68B7EFC-3234-40D0-A553-8475EB5410ED

Q39144187-E97AFCA9-A92F-4589-8371-AE6D9EE94309

Q39144187-F8194135-89A8-4C2C-88C0-5A8F310F324B

Q39144187-F99D292B-0D04-4006-A09B-030538347308

P304

Q39144187-11DEBB61-EDAB-446E-9024-DA94BB233A4F

P31

Q39144187-69D562C0-886F-49B1-8D02-AE9844431A35

P356

Q39144187-0845569B-09C7-4FD5-8EE9-8017F26B5775

P407

Q39144187-2DF6827E-73B6-4D1D-9E67-59BBEC4DC3D9

P433

Q39144187-D3F38A47-B27A-45C1-ABE7-809284CBD7D8

P478

Q39144187-9C2ACF67-2DBC-4E41-9C63-50390D32F611

P577

Q39144187-A8685F36-6335-4780-9BBB-493806727BED

P698

Q39144187-AB7D7433-ED66-4AA1-8E5E-85BE03275683

P356

JNUMED.112.116624

P1433

The Journal of Nuclear Medicine

P1476

99mTc-labeled small-molecule i ...... ar imaging of prostate cancer.

@en

P2093

Craig N Zimmerman

http://www.w3.org/2001/XMLSchema#string

Genliang Lu

http://www.w3.org/2001/XMLSchema#string

John C Marquis

http://www.w3.org/2001/XMLSchema#string

John L Joyal

http://www.w3.org/2001/XMLSchema#string

John W Babich

http://www.w3.org/2001/XMLSchema#string

Kevin P Maresca

http://www.w3.org/2001/XMLSchema#string

Ross D Merkin

http://www.w3.org/2001/XMLSchema#string

Shawn M Hillier

http://www.w3.org/2001/XMLSchema#string

William C Eckelman

http://www.w3.org/2001/XMLSchema#string

P304

1369-1376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.112.116624

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23733925

http://www.w3.org/2001/XMLSchema#string